Journals / Batı Karadeniz Tıp Dergisi / 2026 / Cilt: 9 Sayı: 2

Multisystemic Evaluation in Pediatric Spinal Muscular Atrophy: Linking Biochemical Markers to Functional Outcomes and Family Quality of Life

Pediatrik Spinal Müsküler Atrofide Multisistemik Değerlendirme: Biyokimyasal Belirteçlerin Fonksiyonel Sonuçlar ve Aile Yaşam Kalitesi ile İlişkisi

Nihal Yıldız(ZONGULDAK BULENT ECEVİT UNIVERSITY)0000-0003-0989-842X
Elif Acar Arslan(BIRUNI UNIVERSITY, BİRUNİ RESEARCH CENTER)0000-0002-3284-107X
Pınar Özkan Kart(UNIVERSITY OF HEALTH SCIENCES, TRABZON KANUNİ HEALTH RESEARCH CENTER)0000-0001-5726-737X
Tulay Kamasak(KARADENIZ TECHNICAL UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-5212-0149
Sevim Şahin(KARADENIZ TECHNICAL UNIVERSITY, SCHOOL OF MEDICINE)0000-0001-5415-5874
Ali Cansu(KARADENIZ TECHNICAL UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-1930-6312
Pages
249–254
Publication Date
2025-08-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These factors, along with tailored support for families, should be considered in long-term multidisciplinary management

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Spinal Muscular Atrophy (SMA) is a rare neuromuscular disorder requiring a multidisciplinary approach.
📊
Key Findings & Data:Material and Methods: In this study, 16 genetically confirmed SMA patients aged 2–18 years were evaluated.
💡
Conclusion & Impact:These factors, along with tailored support for families, should be considered in long-term multidisciplinary management
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:İmmünoglobulin · multidisipliner bakım · Spinal müsküler atrofi

Abstract

Aim: Spinal Muscular Atrophy (SMA) is a rare neuromuscular disorder requiring a multidisciplinary approach. This study aimed to investigate the clinical, biochemical, and immunological parameters in pediatric SMA patients and to explore their potential associations with quality of life. Material and Methods: In this study, 16 genetically confirmed SMA patients aged 2–18 years were evaluated. Data on hematologic and biochemical profiles, including vitamin B12, 25-OH-vitamin D3, and immunoglobulin levels, were recorded. The PedsQL™ 3.0 Neuromuscular Module was administered to assess quality of life. Results: The cohort included 8 patients with SMA type 1, 5 with type 2, and 3 with type 3. Seven (43.75%) were females, with a mean age of 93±60 months. The mean follow-up period was 36±5 months. Serum vitamin B12 values were 271±66ng/L, and 25-OH-D3 vitamin values were 21.14±12.9μg/L. Immunoglobulin (Ig) G levels of 5 (31.25%) were below the normal range for their ages. When SMAtype1, SMA type2, and 3 groups were compared, there was no difference in vitamin B12, vitamin D, and IgE levels. Hemoglobin and transferrin saturation were significantly lower in SMA type 1 patients(p<0.05). According to the quality of life assessment of SMA type 2 and 3 patients reported greater financial concerns. All children who completed the questionnaire had similarly low scores. While a decrease in vitamin D level was associated with lower CHOP scores, the relationship was not statistically significant. Conclusion: Even in small cohorts, periodic evaluation of immune and nutritional parameters may reveal clinically relevant findings in SMA. These factors, along with tailored support for families, should be considered in long-term multidisciplinary management

Özet

Amaç: Spinal Müsküler Atrofi (SMA), multidisipliner yaklaşım gerektiren nadir bir nöromüsküler hastalıktır. Bu çalışmada, pediatrik SMA hastalarında klinik, biyokimyasal ve immünolojik parametrelerin değerlendirilmesi ve bu parametrelerin yaşam kalitesi ile olası ilişkilerinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Bu çalışmaya, genetik olarak doğrulanmış ve yaşları 2–18 arasında değişen 16 SMA hastası dahil edilmiştir. Hastaların hemogram ve biyokimyasal profilleri, özellikle vitamin B12, 25-OH-vitamin D3 ve immünoglobulin düzeyleri kaydedilmiştir. Yaşam kalitesini değerlendirmek amacıyla PedsQL™ 3.0 Nöromüsküler Modülü uygulanmıştır. Bulgular: Çalışma grubunu 8 SMA tip 1, 5 SMA tip 2 ve 3 SMA tip 3 hastası oluşturmuştur. Katılımcıların 7’si (%43,75) kız, ortalama yaşları 93±60 aydır. Ortalama takip süresi 36±5 ay olarak belirlenmiştir. Serum vitamin B12 düzeyi ortalama 271±66 ng/L, 25-OH-D3 düzeyi ise 21,14±12,9 μg/L olarak saptanmıştır. Beş hastada (%31,25) yaşlarına göre düşük immünoglobulin G (IgG) düzeyleri tespit edilmiştir. SMA tip 1, 2 ve 3 grupları karşılaştırıldığında, vitamin B12 ve D düzeyleri açısından anlamlı fark bulunmamıştır. Ancak hemoglobin düzeyi ve transferrin saturasyonu SMA tip 1 hastalarında anlamlı olarak daha düşüktü (p<0,05). Yaşam kalitesi değerlendirme ölçeğinde, özellikle SMA tip 2 ve 3 hasta ailelerinde finansal kaygıların ön planda olduğu, tüm çocukların ise benzer skorlar aldığı görülmüştür. Vitamin D düzeyleri ile anket sonuçları karşılaştırıldığında, düşük vitamin D düzeylerinin CHOP skorundaki düşüşle ilişkili olduğu gözlenmiş; ancak bu ilişki istatistiksel olarak anlamlı bulunmamıştır. Sonuç: Küçük örneklem gruplarında dahi, immün ve beslenme ile ilişkili parametrelerin periyodik olarak değerlendirilmesi, SMA hastalarında klinik açıdan anlamlı bulguların ortaya konmasına katkı sağlayabilir. Bu faktörler ve ailelere yönelik bireyselleştirilmiş destek mekanizmaları, uzun vadeli multidisipliner izlem planlarında dikkate alınmalıdır.

🔖

Cite This Article

Yıldız, N., Arslan, E. A., Kart, P. Ö., Kamasak, T., Şahin, S., Cansu, A. (2025). Multisystemic Evaluation in Pediatric Spinal Muscular Atrophy: Linking Biochemical Markers to Functional Outcomes and Family Quality of Life. Batı Karadeniz Tıp Dergisi, Cilt: 9 Sayı: 2, 249–254. https://doi.org/10.29058/mjwbs.1732522

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Prior TW, Finanger E. Spinal muscular atrophy. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993– 2024. [cited 2017 Mar 3]. Available from: https://www.ncbi.nlm. nih.gov/books/NBK1352/
  2. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, Flynn K, Hendrickson BC, Scholl T, Sirko-Osadsa DA, Allitto BA. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27-32. doi: 10.1038/ ejhg.2011.134.
  3. Bahadır Şenol H, Yıldız G, Polat Aİ, Aydın A, Hız AS, Soylu A, Yiş U. Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy. Brain Behav. 2025;15(1):e70221. doi: 10.1002/brb3.70221.
  4. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin. 2015;33(4):831-46. doi: 10.1016/j.ncl.2015.07.004.
  5. Spinraza [package insert]. Cambridge, MA: Biogen; [date unknown] [cited 2024 Jul 31]. Available from: https://www.spinraza. com/content/dam/commercial/spinraza/caregiver/en_us/ pdf/spinraza-prescribing-information.pdf
  6. Goedeker NL, Gibbons JL, Varadhachary AS, Connolly AM, Zaidman CM. Laboratory monitoring of nusinersen safety. Muscle Nerve. 2021;63(6):902-905. doi: 10.1002/mus.27217.
  7. Stolte B, Nonnemacher M, Kizina K, Bolz S, Totzeck A, Thimm A, Wagner B, Deuschl C, Kleinschnitz C, Hagenacker T. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. J Neurol. 2021;268(12):4667-4679. doi: 10.1007/s00415-021-10569-8.
  8. Ioos C, Leclair-Richard D, Mrad S, Barois A, Estournet- Mathiaud B. Respiratory capacity course in patients with infantile spinal muscular atrophy. Chest. 2004;126(3):831-7. doi: 10.1378/chest.126.3.831.
  9. Davis SE, Hynan LS, Limbers CA, Andersen CM, Greene MC, Varni JW, Iannaccone ST. The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales. J Clin Neuromuscul Dis. 2010;11(3):97-109. doi: 10.1097/CND.0b013e3181c5053b.
  10. Aton J, Davis RH, Jordan KC, Scott CB, Swoboda KJ. Vitamin D intake is inadequate in spinal muscular atrophy type I cohort: correlations with bone health. J Child Neurol. 2014;29(3):374- 80. doi: 10.1177/0883073812471857.
  11. Alemdaroglu-Gurbuz I, Bulut N, Bozgeyik S, Ulug N, Arslan SS, Yilmaz O, Karaduman A. Reliability and validity of the turkish translation of pedsqlTM multidimensional Fatigue scale in Duchenne Muscular Dystrophy. Neurosciences (Riyadh). 2019;24(4):302-310. doi: 10.17712/nsj.2019.4.20190035.
  12. Yao M, Ma Y, Qian R, Li Y, Liang Y, Zhang H, Feng Y, Ding M, Zhao X, Li H. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. Orphanet J Rare Dis 16, 7 (2021). Https://doi.org/10.1186/s13023-020-01638-8.
  13. Mozzoni J, Gómez S, Monges MS, de Castro Pérez MF, Méndez M, Lemme P, Avanza R, Toobe M, Paoletti L. Validation of the Pediatric Quality of Life Inventory™, Neuromuscular Module, version 3.0 in Spanish for Argentina. Arch Argent Pediatr. 2021;119(4):e286-e297. doi: 10.5546/aap.2021.eng.e286.
  14. Detering NT, Zambon A, Hensel N, Kothary R, Swoboda K, Gillingwater TH, Baranello G; Workshop participants; Industry participants. 264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th - 21st 2021. Neuromuscul Disord. 2022;32(8):697-705. doi: 10.1016/j.nmd.2022.06.005.
  15. Vai S, Bianchi ML, Moroni I, Mastella C, Broggi F, Morandi L, Arnoldi MT, Bussolino C, Baranello G. Bone and Spinal Muscular Atrophy. Bone. 2015;79:116-20. doi: 10.1016/j. bone.2015.05.039.
  16. Pires M, Marreiros H, Francisco RC, Soudo A, Vieira JP. Atrofia muscular espinhal: análise descritiva de uma série de casos [Spinal muscular atrophy: descriptive analysis of a case series]. Acta Med Port. 2011 Dec;24 Suppl 2:95-102. Portuguese. Epub 2011 Dec 31. PMID: 22849891.